The Phase 3 ACHIEVE-4 trial found that Foundayo (orforglipron) reduced the risk of major cardiovascular events by 16% and cardiovascular death by 53% compared to insulin glargine in adults with type 2 diabetes and obesity. It also improved blood sugar control, weight loss, and other heart health markers. The trial confirms Foundayo's cardiovascular safety and suggests it could offer broader health benefits with a convenient once-daily pill. Lilly is continuing research with the ATTAIN-OUTCOMES study to further evaluate cardiovascular effects.
Eli Lilly's stock price is USD 1,162.60 on Pluang as of Oct 01, 2026 05:11 WIB, showing a 1.98% decline in one day. The company's market cap stands at $1.06 trillion, reflecting its significant presence in the health sector. Pluang investors currently favor buying with 77% of order activity leaning that way, despite the recent price drop.
EBGLYSS (lebrikizumab-lbkz) monotherapy achieved its primary endpoint in the Phase 3b ADtouch trial, with over half of patients showing clear or almost clear skin on hands and feet by Week 16. The treatment also provided significant itch and pain rel...
Novo Nordisk's analysis of real-world data shows that patients who switched from obesity injections like Wegovy or Lilly's Zepbound to Novo's new Wegovy pill continued to lose weight, shedding about 4% of their body weight on average after three mont...
Eli Lilly is growing faster than any other large drugmaker, driven by strong sales of Mounjaro and new FDA approvals for cardiovascular risk reduction and insulin products. The company plans to seek approval for retatrutide in early 2027, a drug show...
Navitas Semiconductor's shares rose 12% premarket after securing a U.S. Army contract to develop next-generation silicon carbide power semiconductor technology. This project aims to create a domestic manufacturing process for ultra-high-voltage silic...
Eli Lilly's Foundayo (orforglipron) 17.2 mg showed significantly greater weight loss (1.5% more) and A1C reduction (0.3% more) than oral semaglutide 25 mg after 52 weeks in adults with type 2 diabetes, based on an indirect comparison of ACHIEVE-3 and...
